

IBC Meeting Minutes  
January 27, 2026 11AM, Zoom Virtual Meeting

**1. CALL TO ORDER:**

1. The meeting was called to order at: 11:04 am
2. In Attendance:
  - a. Ken Malcolm (Chair)
  - b. Cristina Penaranda (Co-Chair)
  - c. Tom Merry (Non-Affiliated community member)
  - d. Vanessa Rodriguez (Member/administrator)
  - e. Katie Kopf (Animal Expert/Veterinarian)
  - f. Peter Farina (Safety Officer)
  - g. Matthew D. Rosenbaum (Animal Expert/Veterinarian)
3. Non Attendance: Joanne E. Streib (Technical Member) and Doria Cladis (Non-Affiliated community member)
4. Guest: Kyla Sumter, BRANY
5. Review and approval of the minutes: None

**2. PROTOCOLS AND ADDENDA:**

1. **BH-Gupta-01-26. Arnav Gupta New Study Review. Reviewer: Ken Malcolm**  
**Discussion:** The reviewer presented the submission to the committee noting the study will involve rDNA, human samples, and gene editing. The PI has submitted the appropriate appendices for this research and has appropriately identified the risk groups and biosafety levels.

Modifications and/or Clarification Requested:

1. In Section I.5, add a new row for K718 and check the BSC Class II box for K718
2. In Section II.7 table, #3, for use of human cells, should be checked.
3. In the Section II.8 table, add the Biosafety Level to be Used as BL2.

Appendix C

1. Question B: If using recombinant Cas9 then only gRNA is on the plasmid vector, NO should be checked here.
2. The table in part E, No should be checked for whether the CRISPR system can self-insert into germ cells.
3. Section E. table no should be selected for germ lines

Lab sign

1. Add room # for both K717 and K718

Determination and vote: The committee voted to approve with modifications as indicated above.

Total: 7      **For: 7**      Against: 0      Abstentions: 0

2. **BH-Mould-01-26. Kara Mould, MD. New Study Review. Reviewer: Cristina Penaranda**

**Discussion:** The reviewer presented the submission to the committee noting the study will involve rDNA, infectious agents, human samples, live animals, flow cytometry, and use of samples from SARS-CoV-2-positive subjects. Although

Toxins (select agent) is checked, the committee noted this is not correct. The PI has submitted the appropriate appendices for this research and has appropriately identified the risk groups and biosafety levels.

Modifications and/or Clarification Requested:

1. A brief title needs to be added to section I.2
2. Section I.3 the box for Toxins/select agents should not be checked
3. Section I.4 clarify the staff conducting the research
4. Section I.5 remove C120
5. rDNA checklist, box #3 should be checked and clarify if #4 is needed
6. Section II.8, add GFP and under vector type add bacterial plasmids as appropriate if using
7. Clarification is needed regarding the use of Pseudomonas, NTM and M. abscessus. If these are being used they need to be added to Section III.9.
8. Section V.11.C indicates that r/sNA and human material are used in live animals, but the table in section D only shows infectious agents. Boxes for r/sNA, human material and recombinant viral particles should be checked as needed. Flexivent is terminal, so "post" box should be unchecked. Given only ABSL-1 animals are currently allowed on microCT post should be indicated
9. Section 11 D. clarify if manipulations need to be checked, uncheck FlexiVent pre, remove micro CT post infection
10. Section 11.F GFP should be added
11. Section 11.G pseudomonas and NTM should be added as applicable
12. Animal Handling add Human elastase to the human cells
13. Animal Handling add Pseudomonas and NTM

Appendix A:

1. Section iii. Update to clarify the activities being done for this protocol.

Lab sign:

1. Add NTM, pseudomonas and m. abscessus if using. Add AAV6.2 to recombinant DNA section and any rDNA vectors used in human cells of RG-2 pathogens

Determination and vote: The committee voted to approve with modifications as indicated above.

Total: 7      For: 7      Against: 0      Abstentions: 0

3. **BH-Berdyshev-02-20. Evgeny Berdyshev Triennial Review. Reviewer: Cristina Penaranda**

**Discussion:** The reviewer presented the submission to the committee noting the study will use human samples. The PI has submitted the appropriate appendices for this research and has appropriately identified the risk groups and biosafety levels.

Modifications and/or Clarification Requested:

1. Section I.1 addendum should not be checked
2. Clarity training plan
3. Human materials section E add brain and heart to human tissues question, and spinal fluid to other

Determination and vote: The committee voted to approve with modifications as indicated above.

Total: 7      **For: 7**      Against: 0      Abstentions: 0

**3. DMR APPROVALS:**

None to Report

**4. APPROVALS:**

None to Report

**5. SOPs and POLICIES:**

None to Report

**6. NEW BUSINESS**

None to Report

**7. OLD BUSINESS**

None to Report

**8. EDUCATION:**

None to Report

**9. MINOR ADMINISTRATIVE:**

**1. Note-to-Files (approved by Chairs):**

None to Report

**2. Personnel Updates:**

None to Report

**3. Annual Reviews:**

a) BH-Alpher-02-21 PI: Scott Alper, PhD. Second annual review approved 1/20/2026.

b) BH-Gorska-02-21 PI: Magdaline Gorska, MD. Second annual review: removal of Subhasmita Mohanty approved 01/20/2026.

**4. Protocol Closures:**

None to Report

**5. Expiration:**

None to Report

**6. Memorandums of Understanding (MOUs)**

None to Report

**10. ADJOURNMENT:**

Meeting Adjourned at: 11:53 am.

**11. ATTACHMENTS**

1. 1/26/2026 IBC Agenda
2. Submission Materials for section II
3. Approved materials for sections III and IV

Respectfully submitted,

Signed by:

*Ken Malcolm*

C3F7497F7B7E403...

---

Ken Malcolm, PhD, IBC Chair

DocuSigned by:

*Vanessa Rodriguez*

5B864EA6E75044B...

---

Vanessa Rodriguez, IBC administrator